medigraphic.com
ISSN 1561-3127 (Electronic)
ISSN 0864-3466 (Print)

2021, Number 4

<< Back Next >>

Revista Cubana de Salud Pública 2021; 47 (4)

Case fatality rates and risk factors by COVID-19 in Mexico

Lara RAL, Parra BGM, López VN

Language: Spanish
References: 24
Page: 1-17
PDF size: 658.89 Kb.


ABSTRACT

Introduction: COVID-19 is a viral disease disseminated worldwide, considered a pandemic with a high mortality rate, whose epidemiological study is fundamental to understand the risk associated with specific populations.
Objectives: Estimate the case fatality rates and risk factors associated with mortality from COVID-19 in the five states with more infections in Mexico.
Methods: 297,230 COVID-19 positive patients were analyzed using RT-PCR tests from 475 monitoring units in five states of Mexico. Case fatality rates and probability ratios were estimated by adjusting a multivariate logistic regression model. Risk factors were considered in a model that included the effects of sex, age, smoking habits, hospitalization history, pneumonia diagnosis, and comorbidities such as diabetes, hypertension, chronic obstructive pulmonary disease, asthma, immunosuppression, chronic kidney disease, and cardiovascular disease, among others.
Results: There is greater contagion among people aged 41 to 60 years. More than 90% of deaths occurred after the age of 41, with the case fatality rate increasing at an older age. Men showed a higher proportion of cases, deaths and case fatality rate. Multivariate logistic analysis showed that age, sex, hospitalization, pneumonia, diabetes, and chronic kidney disease are significant risk factors (p < 0.0001) for COVID-19 mortality.
Conclusions: In Mexico, age, sex, hospitalization, pneumonia, diabetes and chronic kidney disease are factors that increase the risk of mortality from COVID-19. It is suggested to take this information into account to determine vulnerable groups and increase attention to them to reduce, as far as possible, the risk of contagion and mortality.


REFERENCES

  1. Wang C, Horby PW, Hayden FG. A novel coronavirus outbreak of global health concern. The Lancet. 2020;395: 470-73. DOI: 10.1016/S0140-6736(20)30185-9

  2. Rothan H A, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433. DOI: 10.1016/j.jaut.2020.102433

  3. WHO. Coronavirus disease (COVID-19) Situation Report - 142, World Health Organization. Geneva: WHO; 2020 [acceso 10/06/2020]. Disponible en: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200610-covid-19-sitrep-142.pdf?sfvrsn=180898cd_6

  4. The World Bank. Mexico Overview. Mexico: World Bank; 2020 [acceso 14/06/2020]. Disponible en: https://www.worldbank.org/en/country/mexico/overview.

  5. Parra-Bracamonte GM, Lopez-Villalobos N Parra-Bracamonte FE. Clinical characteristics and risk factors for mortality of patients with COVID-19 in a large dataset from Mexico. Annals Epidem. 2020;52:93-98.e2. DOI: 10.1016/j.annepidem.2020.08.005

  6. INEGI. Censos y Conteos de Población y Vivienda. Población. México: INEGI; 15 de marzo de 2015 [acceso 13/07/2020]. Disponible en: https://www.inegi.org.mx/temas/estructura/

  7. INEGI. Encuesta Nacional de Ocupación y Empleo (ENOE), población de 15 años y más de edad. México: INEGI; 2020 [acceso 13/07/2020]. Disponible en: https://www.inegi.org.mx/programas/enoe/15ymas/default.html#Tabulados.

  8. Schwartz DA. An analysis of 38 pregnant women with COVID-19, their newborn infants, and maternal-fetal transmission of SARS-CoV-2: maternal coronavirus infections and pregnancy outcomes. Arch Pathol Lab Med. 2000;144:799-805. DOI: 10.5858/arpa.2020-0901-SA

  9. Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. Am J Respir Crit Care Med. 2020;202:756-59. DOI: 10.1164/rccm.202001-0179LE

  10. Lippi G, Henry BM. Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19). Eur JIntern Med. 2020;75:107-08. DOI: 10.1016/j.ejim.2020.03.014

  11. Chin A, Chu J, Perera M, Hui K, Yen HL, Chan M, et al. Stability of SARS-CoV-2 in different environmental conditions. The Lancet Microbe. 2021;1:e10. DOI: 10.1016/S2666-5247(20)30003-3

  12. Gobierno de México. Secretaría de Salud. COVID-19. México: Secretaría de Salud; 24 enero 2020 [acceso 13/07/2020]. Disponible en: https://coronavirus.gob.mx/covid-19/.

  13. National Institutes of Health. Covid-19 Treatment Guidelines. Maryland: NIH; 2020 [acceso 14/07/2020]. Disponible en: https://www.covid19treatmentguidelines.nih.gov/introduction

  14. To KKW, Tsang OTY, Leung WS, Tam AR, Wu TC, Lung DC, Lau DPL. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20:565-74. DOI: 10.1016/S1473-3099(20)30196-1

  15. Mattiuzzi C, Lippi G. Which lessons shall we learn from the 2019 novel coronavirus outbreak?. Annals Trans Med. 2020;8:1-4. DOI: 10.21037/atm.2020.02.06

  16. Bai HX, Hsieh B, Xiong Z, Halsey K, Choi JW, Tran TM, et al. Performance of radiologists in differentiating COVID-19 from viral pneumonia on chest CT. Radiology. 2020;296: E46-E54. DOI: 10.1148/radiol.2020200823

  17. Bello-Chavolla OY, Rojas-Martinez R, Aguilar-Salinas CA, Hernández-Avila M. Epidemiology of diabetes mellitus in Mexico. Nutr Rev. 2017;75(suppl 1):4-12. DOI: 10.1093/nutrit/nuw030

  18. ENSANUT. Encuesta Nacional de Salud y Nutrición, Presentación de Resultados. Secretaría de Salud, Instituto Nacional de Salud Pública, Instituto Nacional de Estadística y Geografía. México: Secretaría de Salud; 2018. p. 42. Disponible en: https://ensanut.insp.mx/encuestas/ensanut2018/doctos/informes/ensanut_2018_presentacion_resultados.pdf

  19. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. J Virology. 2020;94(7):e00127-20. DOI: 10.1128/JVI.00127-20

  20. Lippi G, Wong J, Henry B. M. Hypertension and its severity or mortality in Coronavirus Disease 2019 (COVID-19): a pooled analysis. Pol Arch Intern Med. 2020. 130(4):304-09. DOI: 10.20452/pamw.15272

  21. Toru Ü, Ayada C, Genç O, Sahin S, Arik Ö, Bulut I. Serum levels of RAAS components in COPD. Eur Respir J. 2015;46(Suppl 59):PA3970. DOI. 10.1183/13993003.congress-2015.PA3970

  22. Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Lian N. et al. The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis. J. Med Virol. 2020;92:1915-1921. DOI: 10.1002/jmv.25889

  23. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97:829-838. DOI: 10.1016/j.kint.2020.03.005

  24. Parra-Bracamonte GM, Parra-Bracamonte FE, Lopez-Villalobos N, Lara-Rivera A. L. Chronic kidney disease is a very significant comorbidity for high risk of death in patients with COVID-19 in Mexico. Nephrology. 2021;26(3):248-251. DOI: 10.1111/nep.13827




2020     |     www.medigraphic.com